Targeted Delivery of Liposomal Temozolomide Enhanced Anti-Glioblastoma Efficacy through Ultrasound-Mediated Blood–Brain Barrier Opening

Glioblastoma (GBM) is the commonest form of primary brain tumor in the central nervous system, with median survival below 15 months and only a 25% two-year survival rate for patients. One of the major clinical challenges in treating GBM is the presence of the blood–brain barrier (BBB), which greatly...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zhuqing, Huang, Xiuxian, Wang, Jieqiong, Cai, Feiyan, Zhao, Ping, Yan, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401148/
https://www.ncbi.nlm.nih.gov/pubmed/34452234
http://dx.doi.org/10.3390/pharmaceutics13081270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401148/
https://www.ncbi.nlm.nih.gov/pubmed/34452234
http://dx.doi.org/10.3390/pharmaceutics13081270

Ejemplares similares